Respiratory syncytial virus entry inhibitors targeting the F protein.
Respiratory syncytial virus entry inhibitors targeting the F protein.
复制标题
针对 F 蛋白的呼吸道合胞病毒侵入抑制剂
DOI:
10.3390/v5010211
复制
发表时间:
2013-01-16
期刊:
影响因子:
--
通讯作者:
Lu L
中科院分区:
文献类型:
--
作者:
Sun Z;Pan Y;Jiang S;Lu L
Human respiratory syncytial virus (RSV) is the main viral cause of respiratory tract infection in infants as well as some elderly and high-risk adults with chronic pulmonary disease and the severely immunocompromised. So far, no specific anti-RSV therapeutics or effective anti-RSV vaccines have been reported. Only one humanized monoclonal antibody, Palivizumab, has been approved for use in high-risk infants to prevent RSV infection. Ribavirin is the only drug licensed for therapy of RSV infection, but its clinical use is limited by its nonspecific anti-RSV activity, toxic effect, and relatively high cost. Therefore, development of novel effective anti-RSV therapeutics is urgently needed. The RSV envelope glycoprotein F plays an important role in RSV fusion with, and entry into, the host cell and, consequently, serves as an attractive target for developing RSV entry inhibitors. This article reviews advances made in studies of the structure and function of the F protein and the development of RSV entry inhibitors targeting it.
登录
查看更多内容
DOI:
10.1056/nejmoa0804877
发表时间:
2009-02-05
期刊:
The New England journal of medicine
影响因子:
--
作者:
Hall CB;Weinberg GA;Iwane MK;Blumkin AK;Edwards KM;Staat MA;Auinger P;Griffin MR;Poehling KA;Erdman D;Grijalva CG;Zhu Y;Szilagyi P
通讯作者:
Szilagyi P
影响因子:
7.3
作者:
Bonfanti, Jean-Francois;Meyer, Christophe;Andries, Koen
通讯作者:
Andries, Koen
影响因子:
4.9
作者:
Cianci, C;Yu, KL;Krystal, M
通讯作者:
Krystal, M
影响因子:
3.1
作者:
Jiang, SB;Lin, K;Debnath, AK
通讯作者:
Debnath, AK
影响因子:
5.4
作者:
Chaiwatpongsakorn, Supranee;Epand, Raquel F.;Peeples, Mark E.
通讯作者:
Peeples, Mark E.